ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

IMTX Immatics NV

12,58
0,00 (0,00%)
Avant marché
Dernière mise à jour : 10:30:03
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Immatics NV IMTX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
0,00 0,00% 12,58 10:30:03
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
12,58
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
14/5/202413:00GLOBEImmatics Announces First Quarter 2024 Financial Results and..
21/3/202412:00GLOBEImmatics Announces Full Year 2023 Financial Results and..
22/1/202418:52EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/1/202414:58EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/1/202402:30GLOBEImmatics Announces Pricing of $175 Million Public Offering
17/1/202422:11EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
17/1/202422:01GLOBEImmatics Announces Proposed Public Offering
16/1/202410:06PRNUSDISCO Pharmaceuticals launches as the surfaceome company..
16/1/202409:59PRNUSDISCO Pharmaceuticals launches as the surfaceome company..
30/11/202310:00GLOBELevicept Appoints Eliot Forster as CEO
14/11/202313:00GLOBEImmatics Announces Third Quarter 2023 Financial Results and..
08/11/202313:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/11/202313:00GLOBEImmatics Reports Interim Clinical Data from ACTengine®..
24/10/202313:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/10/202313:00GLOBEImmatics Receives FDA Regenerative Medicine Advanced Therapy..
14/9/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
13/9/202323:03EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
11/9/202313:00GLOBEModerna and Immatics Announce Strategic Multi-Platform..
11/9/202312:33EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/8/202322:11EDGAR2Form F-3 - Registration statement by foreign private issuers
17/8/202313:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/8/202313:00GLOBEImmatics Announces Second Quarter 2023 Financial Results and..
10/8/202313:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/8/202313:00GLOBEImmatics Initiates Phase 1/2 Clinical Trial to Evaluate..
24/7/202313:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/7/202313:00GLOBEImmatics Announces $35 Million Equity Investment from..